A Phase 3 interventional study of ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy and Lymecyclin and corresponding placebos of the experimental arm in Hidradenitis Suppurativa, sponsored by Institut Pasteur. Recruiting at 4 sites in France. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2025-07-09.
Sponsored by Institut Pasteur · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Hidradenitis Suppurativa with a site in France — 15 open to participants now, 25 under way, 10 of them phase 3. Hidradenitis Suppurativa · France.
Among the 53 studies in Hidradenitis Suppurativa with a site in France, this one is the 34th largest by planned enrollment of the 45 interventional ones that give a count, is one of 12 that started in 2025, is one of 20 in phase 3, reaches primary completion later than 9 of the 24 other live ones, and was the 11th registered.
286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.
Browse Hidradenitis Suppurativa studies →15 of the 53 studies in Hidradenitis Suppurativa with a site in France are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in France, United States, Argentina and 9 more countries
Ages 18–100
Sanofi · Sites in France, United States, Argentina and 12 more countries
Ages 18+
Sanofi · Sites in France, United States, Australia and 16 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Healthy volunteers
AbbVie · Sites in France, Argentina, Canada and 15 more countries
Ages 12+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 62 Hidradenitis Suppurativa studies recruiting now, 34 (55%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 59 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 16 · Phase 3 22 · Phase 4 1
First in 2013; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 92 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 214 across the 45 interventional studies, 196 across the 8 observational. Of the 26 that completed or were terminated, 18 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 53 have an industry lead sponsor. The 10 most frequent:
Institut Pasteur is the lead sponsor of 99 studies on the registry; 41 are open to participants now.
Institut Pasteur has 1 study filed under Hidradenitis Suppurativa — fewer than ten, so there is no comparison to draw.
10 of the studies in Hidradenitis Suppurativa with a site in France that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT05821478Phase 3Institut PasteurEfficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients | 2027-02-28 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
| NCT07388446Hospices Civils de LyonMAIT Cells in Hidradenitis Suppurativa | 2027-02-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 53 studies in Hidradenitis Suppurativa with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study evaluates the efficacy of an adapted antibiotherapy in Hurley stage 2 active Hidradenitis Suppurativa patients versus tetracycline derivative
The antibiotic strategy is targeted against specific pathobionts which have been identified in HS lesions by the investigator's team.
Half of participants will receive a 3-week course of ceftriaxone + metronidazole treatment followed by 3 weeks of rifampicin + moxifloxacin + metronidazole combination, then 6 weeks of rifampin + moxifloxacin (experimental groupe), versus a 12 weeks course of lymecycline (control group) Double blind treatment phase will stop at week 12. All patients whatever their randomization arm or their remission status will begin follow-up treatment according to standard care recommendations (Société Française de Dermatologie): lymecycline, doxycycline or cotrimoxazole. Prescription will be upon decision of the investigator.
This maintenance treatment is not experimental.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of HS according to European Dermatology guidelines:
Non inclusion Criteria:
pregnancy, breastfeeding, known allergy to experimental or reference drugs, wheat allergy, tendinopathy, , bradycardia, heart failure, heart rhythm disturbances, hydroelectrolytic disorders, hypokalemia, coagulation disorders, severe liver/kidney dysfunction, porphyria, mandatory use of nonsteroidal anti-inflammatory drugs (NSAIDs) for other medical conditions
Exclusion criteria:
Pregnancy Abnormal result of routine lab tests corresponding to to study treatments Unauthorized drug for the study during all the study (from study treatments interactions listed in the SmPC, Cf. unauthorized drug listed in non-inclusion criteria).
Development of to any of the study products and/or (e.g. lactose, corn starch, riboflavin).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
a 3-week course of ceftriaxone (Rocephin) IV injection (daily dose 2g/day) \+ oral metronidazole (daily dose 1500mg) followed by a 3-week course of oral rifampicin (Rifadin with 10mg/kg/day) + moxifloxacin (Izilox daily dose 400mg) + metronidazole (daily dose 1500mg) followed by a 6-week course of oral rifampicin (Rifadin with 10mg/kg/day) + moxifloxacin (Izilox daily dose 400mg). A placebo for lymecycline will also be administered during this intensive treatment phase
Drug: ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy
12-week course of oral lymecycline (Tetralysal daily dose 452mg) Placebos for all experimental drugs will also be administered during this intensive treatment phase
Drug: Lymecyclin and corresponding placebos of the experimental arm
a 3-week course of ceftriaxone injection + oral metronidazole followed by a 3-week course of oral rifampicin + moxifloxacin +metronidazole followed by a 6-week course of oral rifampicin + moxifloxacin
Also known as: Experimental treatment
12-week course of oral lymecycline.
Also known as: Control treatment
Percentage of patients reaching clinical remission at week 12, defined by an improvement of 90% of the IHS4 score from the baseline (IHS4 (1))
The clinical remission is defined as a 90% improvement of the International Hidradenitis Suppurativa Severity Score (IHS4) at week 12 compared to the baseline. The IHS4 score is a validated composite score developped to assess dynamically HS severity (1). It is calculated by adding the number of inflammatory nodules to the number of abscesses multiplied by 2 and to the number of draining tunnels multiplied by 4. A total score of 3 or less corresponds to mild severity HS, 4-10 to moderate severity HS and 11 or higher to severe disease.
Time frame: at week 12
Change in Physician Global Assessment (PGA)
Physician assessment describe by differents severity : from Clear (no nodule) to Very severe (more than 5 abscesses or fistulas) Score evaluated at baseline / week 6 / week 12/ week 24/ week 52
Time frame: from baseline to week 52
Change in Modified Sartorius score
Score calculated by points from 0 (better) with differents parameters involved such as location / number / size / type of lesions Score evaluated at baseline / week 6 / week 12/ week 24/ week 52
Time frame: from baseline to week 52
Change in Hurley Score
Score described with 3 stages from I (less severity) to III (most severe) Score evaluated at baseline / week 6 / week 12/ week 24/ week 52
Time frame: from baseline to week 52
Change in Hidradenitis Suppurativa Severity Score (IHS4) score
Score calculated by points from \<3pts (Mild) to \> 11pts (Severe) by nb of nodules, nb of abscesses and nb of draining tunnels Score evaluated at baseline / week 6 / week 12/ week 24/ week 52
Time frame: from baseline to week 52
Change in Hidradenitis Suppurativa Clinical Response (HiSCR) score
Global Assessment score of clear, minimal, or mild evaluated by (i) at least a 50% reduction in AN (abscess and nodule count), (ii) no increase in the number of abscesses and (iii) no increase in the number of draining fistulas from baseline Score evaluated at baseline / week 6 / week 12/ week 24/ week 52
Time frame: from baseline to week 52
Change in Dermatology Life Quality Index (DLQI) score (Patient's HS evaluation)
Evaluated with the Dermatology Life Quality Index (DLQI) Score calculated by points from 0 to 30 following patient answers on quality of life questions Score evaluated at baseline / week 6 / week 12/ week 24/ week 52
Time frame: from baseline to week 52
Change of patient pain
Intensity of pain evaluated with the visual analog scale (VAS) from 0 (no pain) to 10 (pain as bad as it could possible be) Score evaluated at baseline / week 6 / week 12/ week 24/ week 52
Time frame: from baseline to week 52
Microbiological bacterial Change on the worst lesion microbiome at W12
By identification of microbiology bacterial metagenomics (by skin lesional swab sample)
Time frame: at baseline and week 12
Microbiological metagenomics Change on the worst lesion microbiome at W12
By identification of multidrug resistant bacteria (by rectal swab sample)
Time frame: at baseline and week 12
Number of pain killers received by patients
Number of pain killers prescribed for flares (acute worsening of one or more HS lesions)
Time frame: from baseline to week 52
Number of antibiotic treatments received by patients
Number of antibiotic treatments prescribed for flares (acute worsening of one or more HS lesions)
Time frame: from baseline to week 52
Time without flare of HS
Evaluated by number of flares reported or not using a patient journal
Time frame: from baseline to week 52
Change in BMI
Calculated by combined weight and height measures
Time frame: from baseline to week 52
Abnormal biological value of Hemoglobin
measured in g/L, compared to normal ranges
Time frame: from baseline to week 12
Abnormal biological value of white cells
measured in units of cells / mm3 , compared to normal ranges
Time frame: from baseline to week 12
Abnormal biological value of neutrophils
measured in units of cells / mm3 , compared to normal ranges
Time frame: from baseline to week 12
Abnormal biological value of platelet count
measured in units of cells / mm3 , compared to normal ranges
Time frame: from baseline to week 12
Abnormal value of AST liver enzyme
AST value \> 4 x Upper limit of normal
Time frame: from baseline to week 12
Abnormal value of ALT liver enzyme
ALT value \> 4 x Upper limit of normal
Time frame: from baseline to week 12
Number of adverse events of all kind
AE defined by SOC and PT according to MedDra dictonnary
Time frame: from baseline to week 52
Non complete drug administration
Evaluated by total number of capsules not taken according to patient journal
Time frame: from baseline to week 12
Not enrolling at this site.
Plan to share: Yes — All IPD that underlie results in a publication
Supporting information: Clinical study report
Time frame: After publication, for 25 years
Access criteria: By publication in scientific journals and / or presented in scientific or medical meetings
Started May 2025 (actual). Primary completion is estimated for Feb 2027, 21 months after the start.
Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's planned 21 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.